Tagged with Novo Nordisk

Turkey As COVID-19 began spreading through the world, the race to understand the disease by scientists and doctors took off. After just a few months, it became apparent that people with diabetes seemed to suffer more severe effects; 50 percent of people diagnosed with COVID-19 also suffered from diabetes. As a…

Turkey Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials, localization and an operational hub overseeing 75 countries. After almost two decades working with the Danish diabetes and obesity giant,…

Singapore Novo Nordisk Singapore’s Praful Chakkarwar explains how he leverages his experience in a range of geographies in his current role, how COVID-19 has helped facilitate the affiliate’s digital transformation, the burden of diabetes and obesity in Singapore, and his experience in bringing innovative new treatments in these fields onto the…

China Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for Drug Evaluation & Inspection analyse the Chinese NMPA’s drug approval list for 2020, including a surge in approvals for locally developed drugs.   In the…

Switzerland Although Switzerland is ahead of many of its competitors in Europe on levels of healthcare innovation, one potential stumbling block is access to and use of data. The country’s decentralised healthcare system means that many data sets are siloed and heterogeneous within regions, creating issues in terms of conducting research…

Taiwan Novo Nordisk’s Steve Profit outlines the progression of the group’s strategy in Taiwan, how the affiliate works with the Taiwanese healthcare system and physicians on diabetes and obesity, the changes that were needed to adapt to the COVID-19 pandemic, and new product launches he is particularly excited about.   Can…

Global The top 10 most-read interviews on PharmaBoardroom in 2020 represents the broad geographic scope we have had in the past year. From Mexico to Morocco and Romania to Riyadh, these local insights help give a more well-rounded global picture of our industry today.   1. Bill Sibold, Executive VP, Sanofi…

China The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from western rivals, a new Pfizer-LianBio agreement, and Thermo Fisher’s new pharma services facility.   China pharma shares fall as western rivals lead in vaccine trials https://www.ft.com/content/c4c8453e-39f6-4aac-83a3-7d16a3f4fa4b…

Switzerland Novo Nordisk Switzerland’s Mads Stoustrup introduces the affiliate’s remarkable process on bringing innovative diabetes and obesity treatments to market in the past four years, the road still to travel to ensure better outcomes for chronic disease patients in Switzerland, and the leadership he hopes to cultivate during the COVID-19 pandemic…

Belgium Axel De Muyt, general manager & VP of Novo Nordisk Belgium and Luxembourg, recounts his journey through the pharma industry, how he has been able to revive the company’s perspectives in Belgium, and the importance of multi-stakeholder collaboration to raise awareness and education around diabetes.   We have a long-term…

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Romania Cecilia Radu of Novo Nordisk Romania shares her tumultuous four years that have seen declining market share and have culminated in launching the company’s first new product onto the market in several years. She reveals that the perception of diabetes in Romania is skewed, as more than 50 percent of…